in the clinically involved skin of CTCL patients. We also show that malignant lymphoma cells, identified by the co-expression of CD4 and TOX (thymus high-mobility group box), in the skin and blood of CTCL patients produce IL-13 and express both receptors. induces CTCL cell growth in vitro and signaling through the IL-13Rα1. Furthermore, antibody-mediated neutralization of IL-13 or soluble IL-13Rα2 molecules can lead to inhibition of tumor cell proliferation, implicating IL-13 as an autocrine factor in CTCL.
Importantly, we established that IL-13 synergize with IL-4 in inhibiting CTCL cell growth and that blocking the IL-4/IL-13 signaling pathway completely reverses tumor cell proliferation. We conclude that IL-13 and its signaling mediators are novel markers of CTCL malignancy and potential therapeutic targets for intervention.
For personal use only. on . by guest www.bloodjournal.org From
INTRODUCTION
Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of lymphomas that primarily affect the skin. The most common forms of CTCL, 1, 2 Mycosis Fungoides (MF) and Sezary Syndrome (SS), are characterized by proliferation of mature CD4 + T-helper cells. 3 Patients with MF usually develop cutaneous patches and plaques, and have an indolent course with a 5-year survival rate of ~87%. [4] [5] [6] In the early stages, T cells reside in the skin and only a few circulate in peripheral blood. 7 However, as the disease progresses, the outcome is often fatal 8, 9 and the 5-year survival rate for patients with widespread manifestation of CTCL beyond the skin is reduced to 25%. 10 In SS, skinhoming malignant T cells are found in peripheral blood and they infiltrate skin profusely, causing scaling erythroderma and severe pruritus. CTCL is difficult to diagnose, especially in the early stages, due to absence of specific markers for malignant lymphocytes, delaying timely treatment and resulting in poor clinical outcomes. 2, 8 A striking feature of CTCL is the restriction of lymphocyte proliferation to the skin, which implies that the affected cells are dependent on the specific cutaneous microenvironment, including cytokines and adhesion molecules. Malignant skininfiltrating cells are accompanied by dermal infiltrates of nonmalignant T cells and other mononuclear cells. These infiltrating cells, as well as resident cells such as keratinocytes and fibroblasts, produce a variety of cytokines that modulate cutaneous inflammation, 11 and are important constituents of the local environment of tumors, fostering proliferation, survival and migration. 12 In the inflammatory context, cytokines that are derived from inflammatory cells play a key role in restricting immune functions, and act concomitantly with suppressive inflammatory cytokines that are secreted by the tumor cells themselves. 13 Attempts to associate a unique cytokine profile with the disease based on skin or blood samples have generally indicated that a shift from Th1 to Th2 cytokine production, [14] [15] [16] [17] [18] accompanies disease progression. Furthermore, Th2 cell-specific transcription factors, such as GATA-3 and JunB, were highly overexpressed in SS, as detected by cDNA microarray analysis. 19 Consequently, a hypothesis emerged in which immune- 
Immunohistochemistry and confocal microscopy
Sequential paraffin-embedded skin biopsies (5μm) from 24 patients with confirmed MF diagnosis were stained with the following anti-human primary mAbs: rat anti-IL-13
(Abcam), rabbit anti-IL-13Rα1 (Sigma), mouse anti-IL-13Rα2 (Abcam) or rabbit antipSTAT-6 (Abcam), as previously described. 41 Skin samples were observed using an Olympus BX40 microscope. Images were acquired using a Leica DFC420 camera and 
Statistical analysis
Statistical analyses were performed using Prism (GraphPad Software). We used the unpaired two-tailed Student's t-test to compare two groups. Multiple group comparisons were made by one-way ANOVA followed by a post-hoc Dunnett's test or a Tukey's test.
We considered p<0.05 (indicated * in Figures) as significant, p<0.01 (**) as very significant, and p<0.001 (***) as highly significant. 
RESULTS

IL-13 expression by tumor cells in the skin lesions of CTCL patients.
By conventional immunohistochemistry, we compared IL-13 expression in skin lesions of CTCL patients with that of NS, AD and psoriasis skin. We analyzed samples from CTCL patients ranging from IA through IVA stage disease. All patients had established CD4 + malignant phenotype. As expected, NS was negative for IL-13 expression, 41 while high numbers of IL-13 + cells were found in the epidermis and dermis of AD skin 47 and none in psoriasis. 48 In CTCL skin biopsies, IL-13 protein was detected in mononuclear cells associated with malignant cell aggregates ( Figure 1A ). Figure 2B and Supplemental Table I ).
To establish whether IL-13 expression was specific to tumor cells or was associated with the inflammatory cells infiltrating the tumor, we performed multicolor immunofluorescence analysis of well-characterized CTCL skin biopsies staining for IL-13 and tumor markers. Malignant CTCL cells were identified both by CD4 positivity and TOX expression. [49] [50] [51] Indeed, TOX is only expressed by ~60% of CD4 + T cells in skin biopsies from patients with confirmed CTCL diagnosis, and it is not expressed by NS or skin from AD ( Figure 1B-C) , a benign inflammatory skin condition which presents some clinical and histological features common to CTCL 50, 52 and harbors a large number of infiltrating CD4 + T lymphocytes. Representative images of IL-13/CD4 or IL-13/TOX costaining are shown in Figure 1D and Supplemental Figure 1A . an important role in the pathogenesis of CTCL.
IL-13 receptor expression in CTCL skin lesions.
IL-13 receptors are expressed in a broad range of cell types, including hematopoietic and non-hematopoietic cells, but not T cells. 53 (Supplemental Figure 1C) . Thus, these results demonstrate that IL-13 receptors are expressed in the blood and skin of CTCL patients and represent novel markers of malignancy in CTCL.
IL-13 neutralization in Sezary cells
To determine whether IL-13 affects proliferation of Sezary cells in vitro, we purified CD4 + T cells from the peripheral blood of SS patients and cultured them for five days with various doses of IL-13. Proliferation of SS CD4 + T cells was assessed by MTT proliferation assay ( Figure 3A) . We found that IL-13 induces proliferation in a dosedependent manner, implicating IL-13 as a potential growth factor for SS cells. In comparing the growth-promoting effect of IL-13 to IL-2, another important growth factor
for Sezary cells 54 , we found that similar concentrations of IL-13 and IL-2 (i.e., 100 ng/ml) have comparable effects on Sezary CD4 + T cell proliferation (Supplemental Figure 2B ).
Next, we investigated signaling via the IL-13 pathway in SS. We determined the phosphorylation of the transcription factor Signal Transducer and Activator of Transcription-6 (pSTAT-6), one of the most significant steps during IL-13 activation. we found it to be a potent activator in freshly isolated CD4 + T cells from patients, indicating signaling through IL-13Rα1 ( Figure 3B ). STAT-6 activation was then studied in CTCL skin biopsies at different disease stages. We found high numbers of pSTAT-6 + mononuclear cells associated with malignant cell aggregates in CTCL skin biopsies of all samples tested ( Figure 3C ). However, patients with Stage IV disease had more pSTAT-6 + cells compared to Stage I patients ( Figure 3D , p<0.05). pSTAT-6 staining was mainly
localized in the nucleus, however some cells exhibited cytoplasmic staining. As expected, there was no expression of pSTAT-6 in NS and only few pSTAT-6 + cells were found in AD skin ( Figure 3D , p<0.001).
Since SS cells produce IL-13, 18 we analyzed whether blocking IL-13 by an anti-IL-13
antibody or a soluble form of the decoy IL-13Rα2 could affect proliferation of SS tumor cells in vitro. Cells were cultured for five days and activated in vitro by anti-CD3/CD28 or Phytohaemagglutinin. By MTT we detected a highly significant anti-proliferative effect after IL-13 blocking ( Figure 3E ) that was confirmed by CFSE staining (Supplemental Previous work implicates IL-13 as an important autocrine factor for several tumors [25] [26] [27] [28] and the expression of IL-13Rα2 represents an important biomarker for several solid malignancies. [29] [30] [31] [32] [33] However, little is known about the role of IL-13 in CTCL, apart from the finding that both CTCL tumor cell lines 56 and SS malignant cells produce IL-13 in vitro.
18
While it is well established that CTCL disease progression is associated with Th2 skewing of the cytokine profile and increasing immunosuppression, 18 IL-13's role as a regulator of tumor cell proliferation has never been addressed. immunologic pathogenesis of both MF and SS, it is not surprising that the same cytokines may play a role in pathogenesis of both diseases. Based on our data, we conclude that IL-13 plays an increasingly important role in progression from early to advanced stages.
Activation of STAT-6 is an important step in the IL-13/IL-4 signaling pathway. Indeed, activation of IL-13 signaling was detected after IL-13 treatment in CD4 + T cells from patients but not in CD4 + T cells from controls. Interestingly, we found that the levels of pSTAT6 were high in freshly isolated SS CD4 + T cells whereas STAT6 is rarely activated in normal CD4 + lymphocytes. Constitutive activation of STAT6 was observed in other malignancies, such as classical Hodgkin lymphoma 58 and primary mediastinal large Bcell lymphoma, 59 which was shown to result from autocrine secretion of IL-13 by tumor cells. Significantly, we found that pSTAT-6 is also highly expressed in CTCL skin and in vivo 64, 65 and showed survival benefit in phase I/II clinical trials of patients with glioblastoma multiforme at doses that do not produce significant toxicity. 66 Therefore, IL-13Rα2 expression in CTCL might represent a marker of malignancy that can be exploited for targeted therapy of the disease.
In addition to its role as a mediator of tumor cell growth, IL-13 may also affect the immune response to CTCL. 
chemokine receptor CCR3. 70 Other aspects of the CTCL phenotype such as eosinophilia, increased IgE production, and bias towards Th2 cells may also be attributable to the effects of IL-13. In addition, while the pro-fibrotic activity of IL-13 is well known, 21 the secretion of IL-13 by CTCL cells may induce a pro-fibrotic phenotype on dermal fibroblasts and underlie the pathogenesis of fibrosis observed in CTCL skin tumors.
We conclude that IL-13 and its receptors are novel biomarkers of CTCL malignancy and critical factors in the disease's etiology. Further, the role of IL-13 in autocrine growth of CTCL cells and paracrine stimulation of the reactive infiltrate suggests that IL-13 and its molecular pathway are highly relevant targets for therapeutical intervention.
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